Jian Ding
Vice President, Translational Research CREATE Medicines
Ph.D. of The University of Freiburg (Germany), Chijian has 10 years’ experience in pharmaceutical industry. Their focus is on circRNA based therapeutics development in the past 6 years.
Seminars
Tuesday 21st July 2026
In Vivo Immune Cell Programming with mRNA-LNP Therapeutics
8:30 am
- In vivo CAR mRNA-LNP platform selectively generates CAR-T, CAR-NK, and myeloid CAR cells directly in patients
- Clinically validated with data from 50+ patients and demonstrated tolerable repeat dosing
- Best-in-class in vivo CARs across oncology and autoimmunity, including first clinical responses with in vivo CARs outside blood cancers
